Pair Name	Celastrol, TNF-related apoptosis inducing ligand
Disease Info	[ICD-11: 2A00]	Glioblastoma multiforme		Investigative
Biological Phenomena	Induction-->Apoptosis
Gene Regulation	Up-regulation	Cleavage	CASP3	hsa836
	Up-regulation	Cleavage	CASP8	hsa841
	Up-regulation	Cleavage	PARP1	hsa142
In Vitro Model	U-87MG ATCC	Glioblastoma	Homo sapiens (Human)	CVCL_0022
	U-251MG	Astrocytoma	Homo sapiens (Human)	CVCL_0021
	LN-229	Glioblastoma	Homo sapiens (Human)	CVCL_0393
Result	The results of our study demonstrate that celastrol sensitizes glioma cells to TRAIL via the death receptor pathway and that DR5 plays an important role in the effects of this cotreatment. The results indicate that this cotreatment is a promising tumor-killing therapeutic strategy with high efficacy and low toxicity.

Pair Name	Celastrol, TNF-related apoptosis inducing ligand
Disease Info	[ICD-11: 2C25]	Lung cancer		Investigative
Biological Phenomena	Induction-->Apoptosis
Gene Regulation	Up-regulation	Activity	CASP3	hsa836
	Up-regulation	Activity	CASP8	hsa841
	Up-regulation	Expression	MAP1LC3A	hsa84557
	Up-regulation	Expression	SQSTM1	hsa8878
In Vitro Model	A-549	Lung adenocarcinoma	Homo sapiens (Human)	CVCL_0023
	HCC15	Lung squamous cell carcinoma	Homo sapiens (Human)	CVCL_2057
	Calu-3	Lung adenocarcinoma	Homo sapiens (Human)	CVCL_0609
Result	The combined use of TRAIL with celastrol may serve as a safe and adequate therapeutic technique for the treatment of TRAIL‑resistant lung cancer, suggesting that celastrol‑mediated autophagy flux inhibition sensitized TRAIL‑initiated apoptosis via regulation of ROS and ΔΨm.